Get started
Author

Stefano Lucherini

Observed names: Lucherini, Stefano, S Lucherini, S. Lucherini
ORCID: 0000-0001-6410-6865
Observed ORCID: 0000-0001-6410-6865
OpenAlex ID: A5020747166
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis
2018 · Ruben Mujica-Mota, Jo Varley-Campbell, et al. · Health Technology Assessment · 26
PDF
Treatment Options for Dementia with Lewy Bodies: A Network Meta-Analysis of Randomised Control Trials
2020 · Amir A. Tahami Monfared, Mitesh Desai, et al. · Neurology and Therapy · 9
PDF
Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany
2025 · Alastair Greystoke, Melinda J. Daumont, et al. · BMC Pulmonary Medicine · 5
Biomarkers of nivolumab benefit in resectable non-small cell lung cancer
2026 · Tina Cascone, Mark M. Awad, et al. · Nature · 3
PDF
Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis
2024 · Nicolas Girard, Mariam Besada, et al. · Cancers · 3
Cost-effectiveness of perioperative nivolumab + neoadjuvant platinum doublet chemotherapy as treatment for resectable non-small cell lung cancer in the United States
2025 · Benjamin White, Mack Harris, et al. · Journal of Medical Economics · 2
Pcn141 Use of Cost-effectiveness Affordability Curves in Evaluating Cancer Drugs in England
2019 · Y. Yi, S. Lucherini · Value in Health · 2
Assessing the impact of PD-1/PD-L1 inhibitors on health and budget in Belgium
2018 · J van Bavel, S Lucherini, et al. · European Journal of Public Health · 2
PDF
PD44 Multi-Comparator Incremental Cost-Effectiveness Ratio: A New Framework For Cost-Effectiveness Analysis
2018 · Stefano Lucherini, Robert Hughes, et al. · International Journal of Technology Assessment in Health Care · 2
PDF
Assessing The Joint Probability Of Cost-Effectiveness And Affordability In Decision Making
2017 · Y Yi, S Lucherini, et al. · Value in Health · 2
208P: Pathological response after neoadjuvant chemotherapy (chemo) and nivolumab (NIVO) in resectable non-small cell lung cancer (NSCLC): Initial results from a French multicenter real-world (rw) retrospective study
2025 · N. Girard, Q. Thomas, et al. · Journal of Thoracic Oncology · 1
PDF
PP39 Budget Projections And Health Impact Of PD-1/PD-L1 Inhibitors
2019 · Alexander Roediger, Julie van Bavel, et al. · International Journal of Technology Assessment in Health Care · 1
PDF
Budget and Health Impact of the PD-1/PD-L1 inhibitor class in Austria
2018 · J van Bavel, S Lucherini, et al. · European Journal of Public Health · 1
Projecting the budget and health impact of PD-1/PD-L1 inhibitors in Slovenia
2018 · J van Bavel, S Lucherini, et al. · European Journal of Public Health · 1
PDF
588 Comparing treatment strategies in resectable non-small cell lung cancer: insights from multiple network meta-analysis approaches
2026 · Tina Cascone, Jonathan D Spicer, et al. · Journal for ImmunoTherapy of Cancer
PDF
EP07.30: Patient and Physician Preferences for Perioperative Treatment Attributes in Potentially Resectable Non-Small Cell Lung Cancer
2026 · S. Schmid, H. Horinouchi, et al. · Journal of Thoracic Oncology
P1.288: Real-World Outcomes for First-Line Nivolumab + Ipilimumab + Chemotherapy in PD-L1<1% Metastatic Non-Small Cell Lung Cancer
2026 · M. Dietrich, L. Bazhenova, et al. · Journal of Thoracic Oncology
Msr63 Target Trial Emulation (tte) Informed by Clinical Trial Data: Adjuvant Nivolumab Vs Observation in Patients With Resectable Non-small Cell Lung Cancer (rnsclc) After Neoadjuvant Nivolumab Plus Chemotherapy and Surgery
2026 · Greta Lozano-Ortega, Basia Rogula, et al. · Value in Health
PDF
EE264 Cost-Effectiveness of Nivolumab Plus Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable NSCLC in Greece
2025 · Mack S. Harris, Fotios Diamantogiannis, et al. · Value in Health
EPH148 Insights From a French Postmarketing Authorization Early Access (MA EA) Mechanism: Projecting Clinical and Economic Benefits of Neoadjuvant Nivolumab–Platinum-Based Chemotherapy (PDC) in Resectable Non-Small Cell Lung Cancer
2025 · Paul Casabianca, Jérémy CARETTE, et al. · Value in Health
Cost-effectiveness of Nivolumab + Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer in England
2025 · Joel Russell, Mack Harris, et al. · Oncology and Therapy
PDF
282P Impact of artificial intelligence (AI) on follow-up of incidental lung nodules: A US multi-center ambispective study
2025 · J. Pannu, N. Hill, et al. · ESMO Real World Data and Digital Oncology
PDF
PCR137 Patient and Physician Perspectives on Attributes of IO-Containing? Perioperative Treatments in Potentially Resectable, Non-metastatic Non-small Cell Lung Cancer (NSCLC)
2025 · Matthew Quaife, Erica Visintin, et al. · Value in Health
Correction: Girard et al. Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis. Cancers 2024, 16, 2492
2025 · Nicolas Girard, Mariam Besada, et al. · Cancers
PDF
Analyse médicoéconomique de nivolumab + CT néoadjuvante dans le CBNPC exprimant PDL1 ≥ 1 % en France : une stratégie moins coûteuse et plus efficace que la CT néoadjuvante
2025 · P. Casabianca, J. Carette, et al. · Revue des Maladies Respiratoires Actualités
Works count: 47
Citation count: 60
H-index: 3
I10-index: 1
Year
Topic
Type